Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)
Status:
Completed
Trial end date:
2022-02-13
Target enrollment:
Participant gender:
Summary
Despite the use of various treatment strategies, poor response to ovarian stimulation remains
a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus
less likely to conceive with high risk of cycle cancellation. The aim of this study is to
evaluate the effect of recombinant human GH administration to gonadotropins on clinical and
laboratory ICSI outcomes in expected poor responders more and less than 35 years (Poseidon
group 4 and 3 respectively).